Drug Profile
Research programme: tuberculosis therapies - Summit
Latest Information Update: 18 Mar 2013
Price :
$50
*
At a glance
- Originator VASTox
- Developer Eli Lilly and Company; Summit Therapeutics
- Class
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 18 Mar 2013 No development reported for Tuberculosis in United Kingdom (unspecified route)
- 20 Jul 2007 VASTox is now called Summit
- 14 Aug 2005 Preclinical trials in Tuberculosis in United Kingdom (unspecified route)